Magnus Medical key facts
as of Oct 2026- Developer of a brain stimulation technology designed to treat neurological and psychiatric disorders.
- Magnus Medical is valued at approximately $65.0M as of Oct 2026 (last reported valuation).
- It has raised $89.0M across 2 recorded rounds; the latest was Early Stage VC ($49.0M) in May 2025.
- Notable investors include Dolby Family Ventures, JAZZ Venture Partners, Maj Invest, Red Tree Venture Capital, Still Capital Partners.
- Magnus Medical has filed 2 Form Ds with the SEC, most recently May 2025 ($23.7M sold to 6 investors).
- Status: Privately Held (backing).
Magnus Medical's last reported valuation, Dec 2020. Nothing priced has surfaced since.
- ·Watch Magnus Medical: the Monday email on marks, rounds and moves
Magnus Medical funding rounds
2 roundsWho backs Magnus Medical
5Magnus Medical valuation
Magnus Medical's last reported valuation was $65 million in Dec 2020. No priced round, secondary trade or fund mark has surfaced since.
How much has Magnus Medical raised?
Magnus Medical has raised $89 million across 2 recorded rounds since 2025. The largest was a $49 million early-stage round in May 2025.
Magnus Medical has filed 2 Form Ds with the SEC, most recently in May 2025 ($23.7 million sold to 6 investors).
Magnus Medical investors
5 investors are on record for Magnus Medical, including Dolby Family Ventures, JAZZ Venture Partners, Maj Invest and Red Tree Venture Capital. The early-stage round in May 2025 drew 10 investors.
About Magnus Medical
Developer of a brain stimulation technology designed to treat neurological and psychiatric disorders. The company's technology is a novel treatment that has demonstrated profound and rapid results caused by identifiable changes in brain networks, enabling patients to manage their symptoms acutely and restore and sustain mental health.
- Sector
- Healthcare
- HQ
- Burlingame, CA, United States
- Founded
- 2017
- Employees
- 49
- Website
- magnusmedical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.